Analyst Price Targets — MDLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 12:03 pm | Ivan Feinseth | Tigress Financial | $60.00 | $43.41 | TheFly | Medline price target raised to $60 from $55 at Tigress Financial |
| February 25, 2026 7:48 pm | Michael Cherny | Leerink Partners | $56.00 | $48.18 | TheFly | Medline price target raised to $56 from $48 at Leerink |
| February 25, 2026 7:45 pm | — | Stifel Nicolaus | $55.00 | $48.18 | TheFly | Medline price target raised to $55 from $46 at Stifel |
| February 25, 2026 6:37 pm | — | Evercore ISI | $55.00 | $49.38 | TheFly | Medline price target raised to $55 from $50 at Evercore ISI |
| February 5, 2026 2:47 pm | — | Tigress Financial | $55.00 | $45.01 | TheFly | Medline initiated with a Buy at Tigress Financial |
| January 21, 2026 12:16 pm | David Larsen | J.P. Morgan | $55.00 | $43.17 | TheFly | Medline price target raised to $55 from $50 at BTIG |
| January 12, 2026 1:39 pm | — | Barclays | $50.00 | $41.65 | TheFly | Medline initiated with an Overweight at Barclays |
| January 12, 2026 1:17 pm | — | BNP Paribas | $38.00 | $42.19 | TheFly | Medline initiated with a Neutral at BNP Paribas |
| January 12, 2026 12:53 pm | — | Wolfe Research | $47.00 | $41.88 | TheFly | Medline initiated with an Outperform at Wolfe Research |
| January 12, 2026 12:42 pm | — | Deutsche Bank | $40.00 | $40.52 | TheFly | Medline initiated with a Hold at Deutsche Bank |
Latest News for MDLN
We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's…
Continued investment in next-gen supply chain technology powers Medline's distribution capabilities NORTHFIELD, Ill., April 16, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) announced a strategic agreement to implement next-generation warehouse automation from Symbotic, a leader in AI-enabled robotics technology, as part of the company's ongoing efforts to strengthen the resiliency, efficiency and scalability of the…
MDLN faces FDA warning over cGMP lapses in angiographic syringes, citing weak quality controls, CAPA gaps and design flaws despite escalating share price.
Baillie Gifford and Co. bought a new position in shares of Medline (NASDAQ: MDLN) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 10,410,371 shares of the company's stock, valued at approximately $437,236,000. Baillie Gifford and Co. owned 0.79% of Medline as of
Medline (NASDAQ: MDLN - Get Free Report) and MiniMed Group (NASDAQ: MMED - Get Free Report) are both manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk. Profitability This table compares Medline and MiniMed Group's net
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDLN.
U.S. House Trading
No House trades found for MDLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.